Literature DB >> 27789928

PCSK9 inhibitors - clinical applications.

Robert Schmidli1.   

Abstract

Entities:  

Keywords:  LDL cholesterol; alirocumab; bococizumab; evolocumab; ischaemic heart disease; proprotein convertase subtilisin/kexin type 9

Year:  2016        PMID： 27789928      PMCID： PMC5079796          DOI： 10.18773/austprescr.2016.061

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  11 in total

Review 1.  PCSK9 Inhibition: Discovery, Current Evidence, and Potential Effects on LDL-C and Lp(a).

Authors:  Keith C Ferdinand; Samar A Nasser
Journal:  Cardiovasc Drugs Ther       Date:  2015-06       Impact factor: 3.727

2.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

3.  Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

Authors:  James M McKenney; Michael J Koren; Dean J Kereiakes; Corinne Hanotin; Anne-Catherine Ferrand; Evan A Stein
Journal:  J Am Coll Cardiol       Date:  2012-03-28       Impact factor: 24.094

4.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

5.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

Authors:  Marc S Sabatine; Robert P Giugliano; Stephen D Wiviott; Frederick J Raal; Dirk J Blom; Jennifer Robinson; Christie M Ballantyne; Ransi Somaratne; Jason Legg; Scott M Wasserman; Robert Scott; Michael J Koren; Evan A Stein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

6.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

Authors:  Jennifer G Robinson; Michel Farnier; Michel Krempf; Jean Bergeron; Gérald Luc; Maurizio Averna; Erik S Stroes; Gisle Langslet; Frederick J Raal; Mahfouz El Shahawy; Michael J Koren; Norman E Lepor; Christelle Lorenzato; Robert Pordy; Umesh Chaudhari; John J P Kastelein
Journal:  N Engl J Med       Date:  2015-03-15       Impact factor: 91.245

7.  Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.

Authors:  Frederick Raal; Rob Scott; Ransi Somaratne; Ian Bridges; Gang Li; Scott M Wasserman; Evan A Stein
Journal:  Circulation       Date:  2012-11-05       Impact factor: 29.690

Review 8.  Profile of evolocumab and its potential in the treatment of hyperlipidemia.

Authors:  Arrigo F G Cicero; Alessandro Colletti; Claudio Borghi
Journal:  Drug Des Devel Ther       Date:  2015-06-15       Impact factor: 4.162

9.  Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

Authors:  Russell Scott; Richard O'Brien; Greg Fulcher; Chris Pardy; Michael D'Emden; Dana Tse; Marja-Riitta Taskinen; Christian Ehnholm; Anthony Keech
Journal:  Diabetes Care       Date:  2008-11-04       Impact factor: 19.112

10.  Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Authors:  Peter H Jones; Radhika Nair; Kamlesh M Thakker
Journal:  J Am Heart Assoc       Date:  2012-12-19       Impact factor: 5.501
View more
  5 in total

Review 1.  Evolocumab.

Authors: 
Journal:  Aust Prescr       Date:  2016-10-01

Review 2.  Proprotein convertase inhibition: Paralyzing the cell's master switches.

Authors:  Andres J Klein-Szanto; Daniel E Bassi
Journal:  Biochem Pharmacol       Date:  2017-04-27       Impact factor: 5.858

Review 3.  Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.

Authors:  Huimin Sun; Wen Meng; Jie Zhu; Lu Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-03-21       Impact factor: 3.000

Review 4.  Targeted Strategy in Lipid-Lowering Therapy.

Authors:  Ezgi Dayar; Olga Pechanova
Journal:  Biomedicines       Date:  2022-05-08

5.  Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells.

Authors:  Si-Shun Gan; Jian-Qing Ye; Lei Wang; Fa-Jun Qu; Chuan-Min Chu; Yi-Jun Tian; Wei Yang; Xin-Gang Cui
Journal:  Onco Targets Ther       Date:  2017-04-12       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.